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Simple Summary: Both cancer and the chemotherapy used to treat it are drivers of cachexia,
a life-threatening body-wasting condition which complicates cancer treatment. Poly-(ADP-ribose)
polymerase (PARP) inhibitors are currently being investigated as a treatment against cancer. Here, we
present paradoxical evidence that they might also be useful for mitigating the skeletal muscle specific
side-effects of anti-cancer chemotherapy or exacerbate them. BGP-15 is a small molecule PARP inhibitor
which protected against irinotecan (IRI)-induced cachexia and loss of skeletal muscle mass and
dysfunction in our study. However, peculiarly, BGP-15 adjuvant therapy reduced protein synthesis
rates and the expression of key cytoskeletal proteins associated with the dystrophin-associated
protein complex and increased matrix metalloproteinase activity, while it increased the propensity
for fast-twitch muscles to tear during fatiguing contraction. Our data suggest that both IRI and
BGP-15 cause structural remodeling involving proteins associated with the contractile apparatus,
cytoskeleton and/or the extracellular matrix which may be only transient and ultimately beneficial or
may paradoxically onset a muscular dystrophy phenotype and be detrimental if more permanent.
Abstract: Chemotherapy-induced muscle wasting and dysfunction is a contributing factor to cachexia
alongside cancer and increases the risk of morbidity and mortality. Here, we investigate the effects
of the chemotherapeutic agent irinotecan (IRI) on skeletal muscle mass and function and whether
BGP-15 (a poly-(ADP-ribose) polymerase-1 (PARP-1) inhibitor and heat shock protein co-inducer)
adjuvant therapy could protect against IRI-induced skeletal myopathy. Healthy 6-week-old male
Balb/C mice (n = 24; 8/group) were treated with six intraperitoneal injections of either vehicle,
IRI (30 mg/kg) or BGP-15 adjuvant therapy (IRI+BGP; 15 mg/kg) over two weeks. IRI reduced
lean and tibialis anterior mass, which were attenuated by IRI+BGP treatment. Remarkably, IRI
reduced muscle protein synthesis, while IRI+BGP reduced protein synthesis further. These changes
occurred in the absence of a change in crude markers of mammalian/mechanistic target of rapamycin
(mTOR) Complex 1 (mTORC1) signaling and protein degradation. Interestingly, the cytoskeletal
protein dystrophin was reduced in both IRI- and IRI+BGP-treated mice, while IRI+BGP treatment
also decreased β-dystroglycan, suggesting significant remodeling of the cytoskeleton. IRI reduced
absolute force production of the soleus and extensor digitorum longus (EDL) muscles, while IRI+BGP
rescued absolute force production of the soleus and strongly trended to rescue force output of the
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EDL (p = 0.06), which was associated with improvements in mass. During the fatiguing stimulation,
IRI+BGP-treated EDL muscles were somewhat susceptible to rupture at the musculotendinous
junction, likely due to BGP-15’s capacity to maintain the rate of force development within a weakened
environment characterized by significant structural remodeling. Our paradoxical data highlight that
BGP-15 has some therapeutic advantage by attenuating IRI-induced skeletal myopathy; however,
its effects on the remodeling of the cytoskeleton and extracellular matrix, which appear to make
fast-twitch muscles more prone to tearing during contraction, could suggest the induction of muscular
dystrophy and, thus, require further characterization.
Keywords: anti-cancer treatments; chemotherapy; PARP-1 inhibitor; BGP-15; skeletal muscle;
cachexia; muscle wasting; myopathy; dystrophin; mechanotransduction
1. Introduction
Cachexia is a chronic and often fatal consequence of cancer and the chemotherapeutic agents
used to treat it. It is a complex wasting syndrome defined as a >5% loss of body mass, which features
lean tissue wasting with or without a loss of fat mass [1], as well as prominent skeletal myopathy
that manifests as both wasting and dysfunction [2–4]. Historically, cancer-related cachexia was
considered a tumor-induced phenomenon; however, mounting evidence suggests that chemotherapy
drugs plays a prominent role in the progression of cachexia independent of the tumor [5–8]. Several
chemotherapeutic agents from different drug classes (and with different mechanisms of action) elicit
skeletal muscle toxicity [9], which, at the molecular level, involves disruption of proteostasis in favor
of protein degradation and mitochondrial dysfunction through which oxidative stress/damage is
escalated [10–12]. Despite these data, most chemotherapeutic agents in clinical utility have not been
evaluated for their potential to induce skeletal myopathy. As such, muscle wasting as a side-effect of
anti-cancer chemotherapy treatment is a largely overlooked factor, despite contributing to dose-limiting
toxicities and poorer survival outcomes [13].
Irinotecan (IRI) is a chemotherapeutic agent commonly utilized as part of anti-cancer treatment
regimens against colorectal, pancreatic and small-cell lung cancer [14–16]. As a potent topoisomerase
I inhibitor [17], IRI treatment causes severe gastrointestinal toxicity, neutropenia and asthenia [18].
Recently, skeletal muscle wasting has also emerged as a major off-target event and is a key prognostic
indicator of mortality in IRI-treated cancer patients [19,20]. Recent studies have established that the
FOLFIRI (Folinic acid.leucovorin, fluorouracil and IRI regimen), in which IRI is a staple (in addition
to toleucovorin and 5-fluorouracil), induces skeletal muscle wasting and dysfunction in otherwise
healthy mice [11]. Although it has never been evaluated independently, IRI likely drives this myopathy,
since treatment with the FOLFOX (Folinic acid/leucovorin), fluorouracil and oxaliplatin) regimen,
which includes leucovorin and 5-fluorouracil but substitutes IRI for oxaliplatin, had no effect on
skeletal muscle [11]. Multi-omics analysis of FOLFIRI-treated mouse muscles [21,22] and in vitro cell
culture studies with IRI [23] implicate mitochondrial dysfunction, characterized by the downregulation
of proteins associated with mitochondrial dynamics and oxidative phosphorylation and reduced
adenosine triphosphate (ATP) synthesis, glucose metabolism and mitochondrial viability in this
myopathy. However, the molecular events occurring up- and/or downstream of the mitochondria that
result in muscle wasting and dysfunction are currently unknown. Therefore, in this study, our first aim
was to characterize the effect of IRI treatment on the skeletal muscular system in vivo and investigate
the underlying molecular mechanisms.
Currently, there is no approved treatment against cachexia, despite many adjuvant therapeutics
having been clinically evaluated (reviewed recently in [24]) Targeting the mitochondria could be
therapeutically advantageous in this regard since they appear implicit in IRI-induced skeletal
myopathy. One potential therapeutic candidate is the small molecule BGP-15, a hydroximic acid
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derivative nicotinic acid-amidoxime [25], which has demonstrated therapeutic potential in treating
skeletal myopathy associated with Duchenne Muscular Dystrophy [26,27], ventilation-induced
diaphragm dysfunction [28–31], sarcopenia [32], diabetes [33–35] and oxaliplatin treatment [36]. BGP-15
inhibits poly-(ADP-ribose) polymerase-1 (PARP-1) [37], a repressor of mitochondrial function [38,39],
and co-induces heat shock protein-70 (HSP-70) [40,41], which increases mitochondrial content, function
and oxidative capacity [42]. HSP-70 activation also plays a role in the maintenance of skeletal muscle
mass, in part, by regulating proteostasis [43]. Key to the success of any adjuvant administered to protect
against the side-effects of chemotherapy is that tumor growth is not accentuated—in a pre-clinical cancer
model, BGP-15 did not affect tumor growth [44], nor did it impact the anti-cancer efficacy of cisplatin [37].
Collectively, these data highlight that BGP-15 may be useful as an adjuvant candidate during anti-cancer
chemotherapy to mitigate cachectic skeletal myopathy. Thus, our secondary aim was to evaluate the
protective efficacy of BGP-15 adjuvant therapy against IRI-induced skeletal myopathy and investigate
the underlying mechanisms through which BGP-15 functions in the chemotoxic environment.
In this study, we conclude that anti-cancer IRI treatment causes significant cachexia featuring
muscle atrophy and dysfunction in mice, which could be attenuated with BGP-15 adjuvant therapy.
For the first time, we show that IRI causes cytoskeletal changes involving the loss of dystrophin protein
expression which negatively impact skeletal muscle mass and function. BGP-15 adjuvant therapy
causes further remodeling as well as pro-mitochondrial activity but makes fast-twitch muscles more
prone to tearing during fatiguing contraction. It is difficult to ascertain from our data whether BGP-15
adjuvant therapy is beneficial in the long term or whether it induces a type of muscular dystrophy
and is therefore deleterious. The potential negative impact of BGP-15 on the skeletal muscular system
when teamed with chemotherapeutic agents should be considered in the broader context of using
PARP inhibitors as staples in anti-cancer therapy.
2. Results
2.1. Irinotecan (IRI) Induces Cachexia Which Is Mitigated by BGP-15
In order to determine the capacity for IRI and IRI+BGP treatment to induce and mitigate cachexia,
respectively, body mass and composition, as well as skeletal muscle mass indices, were assessed.
IRI-treated mice lost ~5% of their body mass over the course of the treatment period, which was
partially mitigated by IRI+BGP treatment (p < 0.05; Figure 1A). When expressed relative to the vehicle
(VEH) group, which gained ~5% of their initial body mass over the treatment period, IRI treatment
caused marked cachexia with a ~10% displacement from normal/expected body mass (p < 0.05;
Figure 1B). Combined IRI+BGP treatment attenuated body mass displacement to <5% (pre-cachexia)
(p < 0.05 compared to IRI; Figure 1B). Unsurprisingly, lean mass data mirrored body mass data, with
IRI treatment inducing a ~5% loss of lean mass compared to VEH, which was also partially mitigated
by IRI+BGP treatment but still significantly lower than VEH control lean mass (p < 0.05; Figure 1C).
There was, however, no protective effect from IRI+BGP treatment on fat mass, with both IRI and
IRI+BGP treatment inducing a ~20% reduction in fat mass compared to VEH (p < 0.05; Figure 1D).
These reductions in body composition indices were not due to differences found in food consumption
between treatment groups (p > 0.05; Figure 1E).
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2.2. IRI Treatment Causes Muscular Atrophy Which Is Nor alized by BGP-15
To explore whether the IRI-induced loss of lean mass was emulated in skeletal muscle, we sought
to determine whether IRI and IRI+BGP treat ent could influence crude mass of a selection of hindlimb
muscles or the cross-sectional area (CSA) of tibialis anterior (TA) fibers. There wer no significant
differences in raw mass or the muscle to body mass ratios between treatment groups for extensor
digitorum longus (EDL), soleus (SOL) or heart muscles (p > 0.05; Figure 2A). However, both TA raw
mass and the TA to body mass ratio were significantly reduced following IRI treatment (p < 0.05),
which was protected against by IRI+BGP treatment (p < 0.05; Figure 2A). Histological fiber size
profiling demonstrated a left shift in the SA frequency distribution induced by IRI treatment, which
was nor liz d to VEH control levels by IRI+BGP treatment (Figure 2B). Furthermore, mean fiber
CSA and the pooled fiber size distribution were also significantly reduced following IRI treatment
compared to VEH (p < 0.05; Figure 2C–E) and IRI+BGP treatment partially rescued both of these
measures (p < 0.05; Figure 2C–E). There was no evidence of muscle damage elicited by IRI treatment
by way of centronucleated fibers and immune cell infiltrate (Figure 2E).
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Figure 2. The effect of irinotecan (IRI) and IRI with BGP-15 (IRI+BGP) treatment on muscle mass and
fiber size. (A) Skeletal muscle masses of extensor digitorum longus (EDL), soleus (SOL), tibialis anterior
(TA) and heart were measured post-mortem and are presented as both raw mass and as a muscle
mass to body mass ratio. TA cross-sections were hematoxylin and eosin (H&E)-stained to assess the
skeletal muscle histological fiber size with data presented as (B) muscle fiber cross-sectional area (CSA)
percentage relativ frequency distribution, (C) the mean group pooled muscle fiber CSA (of all fibers
counted) and (D) the group pooled fiber size distribution. (E) Representativ images of H&E-stained
TA cross-sections show no evidence of muscle damage (e.g., centronucleated fibers and immune cell
infiltrate). Scale bar = 50 µm; * = p < 0.05 compared to VEH, ˆ = p < 0.05 compared to IRI; n = 6–8 for
muscle weights; n = 4–6 for histology.
2.3. IRI Reduces Protein Synthesis which Is Exacerbated by BGP-15
To investigate changes to molecular signaling of protein turnover as a potential mechanism for
IRI-induced muscle fiber atrophy, we initially assessed skeletal muscle protein synthesis signaling
via the in vivo surface sensing of translation (SUnSET) method [45], which measures the rate of
puromycin-labelled peptide production as an indicator of overall protein synthesis rates. IRI treatment
reduced protein synthesis compared to VEH, and surprisingly, IRI+BGP treatment further reduced
protein sy thesis (p < 0.05; Figure 3A,J). These decreases in protein synthes s were independent of
a change in the phosphorylation of eIF2a, a highly characteriz d inhibitor of protein synthesis [46]
(p > 0.05; Figure 3B,J). Given its pro inent role regulating skeletal muscle protein synthesis [47],
we next probed for markers involved in the activation of mammalian/mechanistic target of rapamycin
(mTOR) Complex 1 (mTORC1) signaling and mTORC1’s downstream targets. Interestingly, we
demonstrated no significant differences between treatment groups in AktThr308, p70s6k1Thr389 or
4E-BP1Thr37/46 phosphorylation (p > 0.05; Figure 3C–E,J), although there was a trend for IRI+BGP
treatment to increase p70s6k1 signaling relative to IRI (p = 0.08; Figure 3D,J). There was, however, a
reduction in AktSer473 phosphorylation with both IRI and IRI+BGP treatments (p < 0.05; Figure 3F,J),
a site targeted by mTORC2 (mTOR Complex 2) signaling [48]. On the alternative side of protein
turnover, we saw no significant effect between treatment groups in crude static molecular markers
of protein degradation, i.e., total ubiquitinated proteins, Atrogin-1 or muscle RING-finger protein-1
Cancers 2020, 12, 3810 6 of 28
(MuRF-1) (p > 0.05; Figure 3G–J). Full-length Western blots, densitometry data and total protein data
are provided in Figures S1, S2 and S4 and Table S1.
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2.4. Assessment of Molecular Markers of Sarcolemmal Membrane Integrity
Since IRI+BGP enhanced the IRI-induced reduction in protein synthesis rate without affecting
crude markers of protein degradation, we wanted to investigate whether this might be a consequence
of perturbed mechanotransduction through exploring skeletal muscle structural protein expression.
Utilizing homogenized TA muscles which are from the same hindlimb anterior compartment and
have similar fiber type distributions (i.e., predominately fast-twitch, glycolytic type II fibers) as EDL
muscles, we initially probed for laminin, which links the extracellular matrix (ECM) to the sarcolemmal
membrane. There was no significant effect on the protein expression of laminin between treatment
groups (p > 0.05; Figure 4A,M); however, when we assessed the protein expression of dystrophin, a key
structural protein that connects the sarcolemmal membrane to the actin cytoskeleton, IRI treatment
was found to induce a significant reduction, which was not mitigated by IRI+BGP treatment (p < 0.05;
Figure 4B,M). We then probed other key structural proteins located on the sarcolemmal membrane and
demonstrated that IRI+BGP treatment significantly reduced the protein expression of β-dystroglycan
relative to VEH- and IRI-treated mice (p < 0.05; Figure 4C,M), but there were no significant changes
from treatment to the protein expression of sarcoglycan isoforms α and δ (p > 0.05; Figure 4D,E,M).
There was no significant effect between treatment groups on the protein expression of the intermediate
filament desmin (p > 0.05; Figure 4F,M), a key structural protein that connects the sarcomere to the
subsarcolemmal cytoskeleton. Full-length Western blots, densitometry data and total protein data are
provided in Figures S2 and S4 and Table S1.
It has previously been shown in non-muscle cells that BGP-15 can induce remodeling of plasma
membrane lipid rafts, in part, by a Ras-related C3 botulinum toxin substrate 1 (Rac1) GTPase-dependent
mechanism [49]. Furthermore, Rac1 signaling has been shown to mediate matrix metalloproteinases’
(MMPs) activity in multiple cell types [50–53], which are a group of proteolytic enzymes that can
degrade key structural components of the contractile apparatus assembly and the ECM, such as
troponin and collagen, respectively, to facilitate remodeling [54–56]. As such, we wanted to assess
whether BGP-15 improved muscle mass and function through MMP-9 and MMP-2 activity-dependent
structural remodeling. Consistent with our HSP-70 protein expression data, there was no significant
effect of IRI or IRI+BGP treatment on Rac1 (p > 0.05; Figure 4G,M) or MMP-9 and MMP-2 protein
expression (p > 0.05; Figure 4H,I,M) when probing TA homogenate. However, when we evaluated
MMP-9 and MMP-2 activity in EDL homogenate (EDL muscles have a similar fiber type composition
to TA muscles) via gelatin zymography, we found a strong trend for IRI+BGP treatment to increase
MMP-9 activity relative to VEH (p = 0.08; Figure 4J,N) whilst also significantly reducing MMP-2 activity
compared to VEH and IRI treatments (p < 0.05; Figure 4K,N). We also identified that IRI+BGP treatment
shifted homeostatic MMP activity through increasing the MMP-9 to MMP-2 (MMP-9/MMP-2) activity
ratio compared to VEH and IRI treatments (p < 0.05 and p = 0.06, respectively; Figure 4L,N), an event
likely driven by contractile apparatus/cytoskeletal/ECM remodeling [55–57]. Full-length Western blots,
densitometry data and total protein data are provided in Figures S2 and S4 and Table S1.
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markers of sarcolemmal integrity and extracellular matrix (ECM) remodeling. Western blotting
experiments were undertaken in tibialis anterior (TA) muscle, with samples probed for (A) Laminin,
(B) Dystrophin, (C) β-dystroglycan (β-DGC), (D) α-sarcoglycan (α-SGC), (E) δ-sarcoglycan (δ-SGC),
(F) Desmin, (G) Rac1 and matrix metalloproteinase (MMP) isoforms (H) MMP-9 and (I) MMP-2. Gelatin
zymography experiments were conducted using extensor digitorum longus (EDL) muscle homogenate
(same anterior hindlimb muscle compartment as the TA) to assess the activity of (J) MMP-9 and (K)
MMP-2. (L) The ratio of MMP-9 to MMP-2 was utilized to indicate the shift of gelatinolytic MMP
activity. Western blotting data ar expressed as relative p rcentage of h v hicle (VEH) control group
and (M) representative images are displayed alongside the Coomassie Blue repres ntative image, which
was used as the protein loading control. (N) Representative image of zymography data is displayed.
* = p < 0.05 compared to VEH; ˆ = p < 0.05 compared to IRI; n = 5–8.
2.5. Assessment of Skeletal Muscle Contractile Function
We examined the contractile function of the predominately slow-twitch SOL and the predominately
fast-twitch EDL muscles. We found no significant differences between treatment groups in the
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force–frequency relationships of either SOL or EDL muscles (p > 0.05; Figure 5A,B); however, we
demonstrated that the absolute force production of SOL and EDL muscles was significantly reduced by
IRI treatment (p < 0.05; Figure 5C,D). IRI+BGP treatment was protective against IRI-induced skeletal
muscle dysfunction with absolute force normalization in the SOL muscle (p < 0.05; Figure 5C) and
a strong trend toward improved absolute force production of the EDL muscle (p = 0.06; Figure 5D)
relative to IRI-treated animals. When we accounted for the physiological CSA, there was no significant
effect on specific force production of the SOL compared to VEH (p > 0.05; Figure 5E), but IRI treatment
did reduce specific force production of the EDL (p < 0.05; Figure 5F). Interestingly, there was a trend for
IRI+BGP treatment to improve the specific force production of the SOL relative to both IRI and VEH
groups (p = 0.09; Figure 5E); however, IRI+BGP exhibited no ameliorative effect on the IRI-induced
reduction in specific force production of the EDL (p > 0.05; Figure 5F). Mirroring the absolute force
data, we demonstrated a reduction in the twitch force (Pt) and the rate of force development (df/dt)
for EDL (p < 0.05; Figure 5G) and SOL (p < 0.05 and p = 0.08, respectively; Figure 5G) from IRI
treatment, which was mitigated by IRI+BGP treatment, normalizing twitch force to VEH control levels
(p < 0.05; Figure 5G). We then assessed two factors involved in calcium (Ca2+) handling (i.e., time to
peak tension (TTP) and half relaxation time ( 12 RT)), which may play a role in the underlying mechanism
of IRI-induced dysfunction; however, there was no significant effect of IRI or IRI+BGP treatment on
these measures (p > 0.05; Figure 5G). We also assessed fatigue susceptibility in SOL and EDL muscles
by conducting a fatiguing stimulation protocol that induces a progressive reduction in force output of
~65–75% (Figure 5H,I). There was no significant effect of IRI or IRI+BGP treatment on the fatigability of
SOL muscles (p > 0.05; Figure 5H), nor of IRI treatment on EDL muscles (p > 0.05; Figure 5I). However,
it was observed that IRI+BGP-treated EDL muscles had an increased susceptibility to rupture at the
musculotendinous junction during the fatigue protocol, with 50% (n = 3/6) tearing during the initial
3–4 stimulated contractions and the remaining 50% (n = 3/6) tearing but continuing to be partially
responsive to stimuli (Figure 5I). Despite these ex vivo functional observations, there was no significant
effect of IRI or IRI+BGP-15 on voluntary exercise, with wheel distance (p > 0.05; Figure 5J) and speed
(p < 0.05; Figure 5K) unaffected by treatment over a 24-h assessment period. There was, however, a
strong trend for IRI to reduce overall cage activity, which was not mitigated by IRI+BGP-15 treatment
(p = 0.07 for IRI and p = 0.05 for IR+BGP-15 versus VEH; Figure 5L).
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peak, 12 RT = half relaxation time and df/dt = rate of force production, were also evaluated for SOL and
EDL muscles. Additionally, (H) SOL and (I) EDL muscles underwent fatigue protocols (sequential
supramaximal tetanic stimulations) to assess fatigue susceptibility. To correlate ex vivo function data
with overall physical activity, mice were housed in Promethion metabolic cages containing running
wheels for 24 h prior to endpoint muscle collection. Voluntary wheel running (J) distance and (K) speed
were assessed in addition to (L) cage activity over these 24 h. * = p < 0.05 compare to VEH; # p = 0.08
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2.6. Assessment of Skeletal Muscle Metabolic Phenotype
Since we have previously demonstrated that IRI treatment can reduce skeletal uscle
mitochondrial viability in vitro [58], we undertook itochondrial profiling on muscles d rived
from IRI- and IRI+BGP-treated mice o determine whether similar effects oul be observed. Initially,
we ass ssed citrate synthase (CS) activity in TA homogenate as a marker of mitochondrial density.
While there was no significant effect of IRI treatment, IRI+BGP treatment significantly increased
CS activity compared to the VEH control group (p < 0.05; Figure 6A). Additionally, we conducted
mitochondrial metabolic phenotyping experiments in isolated flexor digitorum brevis (FDB) muscle
using extracellular flux technology to determine the relative contribution of oxidative and glycolytic
metabolism. There was no effect of IRI treatment on the resting basal respiration compared to VEH
(p > 0.05); however, IRI+BGP treatment significantly increased basal respiration compared to VEH and
IRI groups (p < 0.05; Figure 6B). Similarly, ATP production rate was significantly increased by IRI+BGP
treatment compared to the VEH and IRI groups (p < 0.05; Figure 6C); however, there was no significant
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effect of any treatment group on the coupling efficiency (p > 0.05; Figure 6D). Interestingly, IRI treatment
increased spare respiratory capacity relative to VEH (p < 0.05; Figure 6E), although IRI+BGP treatment
had no effect on this mitochondrial functional parameter (p > 0.05; Figure 6E). We also demonstrated
no impact of either IRI or IRI+BGP treatment on glycolytic metabolism as there was no significant
effect of treatment on basal extracellular acidification rate (ECAR) or ECAR metabolic potential, which
is indicative of the maximal ECAR capacity (p > 0.05; Figure 6F,G, respectively).
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mitochondrial metabolic phenotyping. (A) Tibialis anterior (TA) homogenate was analyzed for
citrate synthase (CS) activity as a marker of mitochondrial density. Isolated flexor digitorum brevis
(FDB) fibers were utilized for mitochondrial metabolic analyses with oxidative respiration indices,
i.e., (B) basal respiration, (C) adenosine triphosphate (ATP) production rate, (D) coupling efficiency,
(E) spare respiratory capacity, as well as glycolytic respiration indices, i.e., (F) basal extracellular
acidification rate (ECAR) and (G) ECAR metabolic potential, measured. Furthermore, Western
blotting experiments were undertaken and TA homogenate was probed for (H) total poly-(ADP-ribose)
polymerase-1 (PARP-1) and (I) heat shock protein-70 (HSP-70)—these data are expressed as a relative
percentage of the vehicle (VEH) control group. (J) Western blot representative images are displayed
alongside a Coomassie Blue representative image, which was used as the protein loading control.
* = p < 0.05 compare to VEH; ˆ = p < 0.05 compared to IRI; n = 4–8 for CS activity and n = 5–8 for
metabolic phenotyping and Western blotting.
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To examine whether the mechanisms underlying the enhanced mitochondrial function from
IRI+BGP treatment adhered to the previously confirmed targets of BGP-15 (i.e., HSP-70 co-induction
and PARP-1 inhibition) [26,37], we next undertook Western blotting in TA homogenates. We showed
that IRI+BGP treatment reduced total PARP-1 protein expression (p < 0.05; Figure 6H,J) but did not
alter HSP-70 protein expression (p > 0.05; Figure 6I,J). IRI treatment alone did not significantly affect
either target (p > 0.05; Figure 6H–J). Full-length Western blots, densitometry data and total protein
data are provided in Figures S3 and S4 and Table S1.
2.7. Assessment of Redox Balance and Mitochondrial Content Signaling Pathways in Skeletal Muscle
Since skeletal muscle dysfunction caused by chemotherapeutic agents has previously been
associated with oxidative stress potentiated through increased reactive oxygen species (ROS)
production [59], we wanted to investigate molecular markers of redox balance and mitochondrial
content in skeletal muscle. There was no effect of IRI or IRI+BGP treatment on the protein expression
of 4-Hydroxynoneal (4-HNE), a marker of lipid peroxidation, which is a key hallmark of oxidative
stress [60] (p > 0.05; Figure 7A,L); nuclear factor erythroid 2 (NFE2)-related factor 2 (Nrf-2), the master
transcriptional regulator of the anti-oxidant response to cellular stress (p > 0.05; Figure 7B,L); or the
downstream antioxidant targets of Nrf-2, hemeoxygenase-1 (HO-1) and superoxide dismutase-1 (SOD1)
(p > 0.05; Figure 7C,D,L). Similarly, there was no significant difference in the protein expression of
the negative regulator of Nrf-2, Kelch-like ECH-associated protein 1 (Keap-1), from IRI or IRI+BGP
treatment (p > 0.05; Figure 7E,L). Interestingly, the protein expression of DJ-1, a highly conserved protein
that can positively regulate Nrf-2 activity [61], was significantly increased by IRI+BGP treatment
compared to VEH (p < 0.05; Figure 7F,L), whilst there was a modest trend for IRI treatment to
increase DJ-1 protein expression relative to VEH (p = 0.09; Figure 7F,L).These data were further
supported by normal expression of mitogen-activated protein kinase (MAPK) signaling, i.e., p38, ERK
1/2 and JNK (p > 0.05; Figure 7G–I,L), which is sensitive to acute increases in oxidative stress [62],
between treatment groups. However, there was a modest trend for IRI+BGP treatment to increase
p38 phosphorylation relative to VEH (p = 0.09; Figure 7G,L). Additionally, there were no significant
differences between treatment groups in the protein expression of molecular markers of mitochondrial
remodeling (i.e., cytochrome c (Cyt-c); p > 0.05; Figure 7J,L) and content (i.e., commonly probed
protein subunits of the mitochondrial Complexes I–V; p > 0.05; Figure 7K,L). Full-length Western blots,
densitometry data and total protein data are provided in Figures S1, S3 and S4 and Table S1.
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stress—(G) p38 (Thr180/Tyr182) relative to total p38, (H) extracellular signal-regulated protein kinase 
(ERK1/2; Thr202/Tyr204) relative to total ERK1/2 and (I) c-Jun N-terminal kinase (JNK;Thr183/Tyr185) 
relative to total JNK are displayed. Additionally, mitochondrial stress and content markers (J) Cyt-c 
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subunit NDUFB8, were probed for. These data are expressed as a relative percentage of the vehicle 
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Blue representative image, which was used as the protein loading control. * = p < 0.05 compare to 
VEH; n = 5–8. 
3. Discussion 
This is the first study to examine the effect of IRI treatment and BGP-15 adjuvant therapy on 
skeletal muscle mass and function. Our novel findings show that BGP-15 adjuvant therapy mitigates 
the IRI-induced wasting phenotype, which is underscored by a protective maintenance of skeletal 
muscle mass and fiber size. Fascinatingly, we observed a paradoxical finding where BGP-15 adjuvant 
therapy exacerbated the IRI-induced reduction in protein synthesis independent of mTORC1 
signaling but ameliorated the IRI-induced skeletal muscle dysfunction, whilst also potentiating 
oxidative metabolism, apparently through suppression of PARP-1. While we showed indications of 
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3. Discussion
This is the first study to examine the effect of IRI treatment and BGP-15 adjuvant therapy on
skeletal muscle mass and function. Our novel findings show that BGP-15 adjuvant therapy mitigates the
IRI-induced wasting phenotype, which is underscored by a protective maintenance of skeletal muscle
mass and fiber size. Fascinatingly, we observed a paradoxical finding where BGP-15 adjuvant therapy
exacerbated the IRI-induced reduction in protein synthesis independent of mTORC1 signaling but
ameliorated the IRI-induced skeletal muscle dysfunction, whilst also potentiating oxidative metabolism,
apparently through suppression of PARP-1. While we showed indications of cytoskeletal and/or ECM
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remodeling (through changes to the dystrophin-associated protein complex (DAPC) and the MMP-9 to
MMP-2 ratio) driven by both IRI and the addition of BGP-15, it is difficult to conclude whether these
changes are short-lived and ultimately beneficial or whether they detrimentally progress a muscular
dystrophy-like phenotype. Indeed, IRI+BGP-15 muscles were more prone to tearing due to the shear
stress associated with ex vivo fatiguing contraction, although there was no evidence of histopathology.
3.1. Skeletal Muscle Mass versus Protein Synthesis: The Paradoxical Effect of BGP-15 Adjuvant Therapy
We have demonstrated in this study that IRI induced a cachectic phenotype characterized by
skeletal muscle wasting, i.e., diminished crude TA mass and fiber CSA, mirroring previous data
where IRI administered as part of the FOLFIRI chemotherapy combination regimen contributed to
the induction of cachexia [11,63]. One of the underlying mechanisms of skeletal muscle mass loss
in the cachectic phenotype has been proposed to be impaired protein synthesis rates, which was
first demonstrated by Emery et al. [64] in cachectic cancer patients. More recently, in the absence
of cancer, chemotherapeutic agents such as doxorubicin have been shown to reduce skeletal muscle
protein synthesis rates independent of key mTORC1 and eIF2a regulatory signaling [65,66]. Consistent
with these data, we found that IRI-induced muscle wasting was independent of reduced protein
synthesis through mTORC1 inhibition. This suggests that IRI treatment alone, or in a combination
regimen, can significantly impact skeletal muscle mass, placing IRI amongst doxorubicin and cisplatin
as chemotherapeutic agents with skeletal muscle toxicity profiles [9]. Surprisingly, however, we found
that BGP-15 adjuvant therapy further reduced basal protein synthesis rates. One question that arises
from these data is: how did BGP-15 adjuvant therapy attenuate crude muscle and fiber wasting/atrophy
when protein synthesis was even lower than with IRI treatment alone? While this question remains
herein unanswered, if muscle mass is broadly determined by the balance between protein synthesis
and degradation rates, our data suggest that BGP-15 adjuvant therapy likely decreased the rate of
protein degradation to an even larger extent than the reduction in protein synthesis, leading to a net
increase in protein accretion. BGP-15 has previously been shown to co-induce HSP-70 [26,29,67], and
we postulate that the activation of HSP-70 may be a key factor in regulating (i.e., lowering) protein
degradation [43]. For example, the overexpression of HSP-70 has been shown to partially mitigate the
hindlimb unloading-induced escalation of proteolytic activity [68]. Unfortunately, we were unable
to detect the co-induction of HSP-70 by BGP-15 adjuvant therapy. In a C2C12 muscle cell culture,
we have observed that HSP-70 expression is significantly elevated at 30 min following treatment
with 1mM BGP-15 (administered with chemotherapeutic agent, 5-fluorouracil), reaching a peak at
1 h and subsiding by 2 h (D. Campelj [69]). Our observations are consistent with others describing
BGP-15-mediated HSP-70 induction < 24 h after treatment [26,29,67]. Thus, HSP-70 induction by
BGP-15 is acute. transient and, therefore, undetectable in our study as we harvested muscles 3 days
post the final treatment. A recent study by Salah et al. [28] illustrated that a 10-day treatment course of
daily, high-dose (40 mg/kg) BGP-15 could rescue a range of proteolytic post-translational modifications
induced by ventilation-induced diaphragm dysfunction. In contrast, our data show no effect of
BGP-15 adjuvant therapy on crude static markers of protein degradation (i.e., the protein expression of
atrogin-1, MuRF1 and total ubiquitinated proteins) at the end of the treatment period. However, we
cannot rule out decreased proteasomal and/or lysosomal activity, despite no change in the steady state
levels of these markers, or that changes in the markers may have occurred at an earlier time point.
Clearly, more studies are now required to explore this fascinating phenomenon further.
3.2. The Relationship between Protein Synthesis and Cytoskeletal Re-Modelling: A Potential Role for
Mechanotransduction?
Another question that arises from our data is: what was/were the mTORC1-independent
mechanism(s) responsible for the IRI- and BGP-15-mediated reduction in basal protein synthesis rates?
With regards to IRI treatment, one potential answer may lie in the suppression of Akt phosphorylation
at the Ser473 residue. AktSer473 phosphorylation is indicative of mTORC2 activity [48]; mTORC2 has
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recently emerged as a regulator of plasma membrane homeostasis [70], and specific to skeletal muscle,
sarcolemmal integrity is considered to be sensitive to AktSer473 phosphorylation [71]. Furthermore,
mTORC2 activity has recently been implicated in mechanical overload-induced increases in protein
synthesis and muscle growth (for a review, see [72]). Considering these two points, we postulate that
the reduction in protein synthesis induced by IRI treatment and exacerbated by BGP-15 adjuvant
therapy may be reflective of compromised mechanotransduction underlined by reduced AktSer473
phosphorylation and compromised cytoskeletal stability, although the timing of the cascade of events
is unknown. Indeed, we demonstrated a decrease in dystrophin expression from IRI treatment
(both alone and in combination with BGP-15) alongside a decrease in β-dystroglycan from BGP-15
adjuvant therapy, imitating the step-like reduction observed in protein synthesis rates. Altered
expression of cytoskeletal structural proteins in skeletal muscle of chemotherapy-treated mice has
previously been demonstrated via transcriptomic [73] and proteomic [22] screening; however, follow-up
analysis has not been conducted. Since it has long been speculated that skeletal muscle protein synthesis
regulation is tension-dependent [74], better understanding of the underlying mechanistic control of
the mechanotransduction signaling pathways that influence tension is of significant interest [72,75–80].
Importantly, our data are the first to identify the DAPC in the complex interplay between mTORC2
signaling, mechanotransduction and protein synthesis.
3.3. The Functional Consequence of Cytoskeletal Remodeling by IRI Treatment and BGP-15 Adjuvant Therapy
In this study, we demonstrate that IRI administration reduces skeletal muscle force production in a
muscle/fiber-type-independent manner, which is consistent with the dysfunction induced from other
chemotherapeutic agents [11,81,82]. A contributing factor to IRI-induced skeletal muscle dysfunction may
be the reduction in dystrophin protein expression, a key member of the DAPC, which acts as an anchoring
protein supporting the stability of sarcomeric and sarcolemmal proteins. Swiderski et al. [83] highlight
several amino acid residues in the cysteine-rich and C-terminus domains of the dystrophin protein that are
susceptible to post-translational modifications, including phosphorylation by multiple kinases, such as
Ca2+/calmodulin-dependent kinase, which can impact skeletal muscle function [84]. Indeed, the loss of
dystrophin has been associated with dysregulated Ca2+ signaling [85], which has also been observed as
a key perturbation underlying cisplatin- and doxorubicin-induced skeletal muscle dysfunction [86,87].
Thus, it would be of interest in future investigations to determine the post-translational modifications
to the dystrophin protein when challenged by multiple chemotherapeutic agents, including IRI. Since
BGP-15 adjuvant therapy preserved skeletal muscle contractile function, which has previously been
shown in other myopathic models [27,31,32,67], the reduction in both dystrophin and β-dystroglycan
expression appears not to have the same impact on muscle function as it does in muscular dystrophy
models. That being said, an interesting finding of our study was that IRI+BGP-15-treated EDL muscles
had an increased susceptibility to tear from the shear stress of repeated contractions during our ex
vivo fatigue protocol. This may be due, in part, to the increased force production and the combined
reduction in dystrophin and β-dystroglycan expression in the IRI+BGP-15-treated muscles compared
to the IRI-only-treated muscles. Indeed, protein constituents of the DAPC, such as dystrophin and
β-dystroglycan, play an integral role in preserving skeletal muscle stiffness and elasticity [88], assisting in
the maintenance of cytoskeletal integrity during muscle contraction [89]. In addition, we demonstrated
that BGP-15 adjuvant therapy increased the MMP-9/MMP-2 activity ratio, which is proposed to play
a role in remodeling of the ECM and cytoskeletal structural and contractile proteins in skeletal [56]
and cardiac muscle [55]. While the order of remodeling events cannot be ascertained from our data,
these events combined might account for proneness to musculotendinous rupture in IRI+BGP-15-treated
muscles, Future studies are required to elucidate the muscle- and ECM-specific remodeling that is
induced by IRI and BGP-15.
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3.4. BGP-15 Adjuvant Therapy Potentiates Skeletal Muscle Oxidative Metabolism through PARP-1 Inhibition
In this study, BGP-15 adjuvant therapy enhanced skeletal muscle oxidative metabolism, highlighted
by the increase in basal oxygen consumption rate, ATP production and CS activity. The pro-oxidative
metabolic effect of BGP-15 adjuvant therapy appears to be driven via the inhibition of PARP-1 and
perhaps even as a latent effect of the transient co-induction of HSP-70 [26,29,67] in response to IRI
treatment. PARP-1 inhibition exerts cellular protection in environments with excess PARP-1 activity,
which is considered to promote destabilization of the mitochondrial membranes, leading to the
impairment of mitochondrial function [90]. While we saw no evidence of increased PARP-1 or
reduced mitochondrial function elicited by IRI treatment, PARP-1 inhibition by BGP-15 still inferred
pro-mitochondrial activity. This could be due to the timepoint at which we harvested tissue (i.e., 3
days post final IRI injection), which may have preceded the acute mitochondrial perturbations elicited
by IRI, as previously published by us in C2C12 myoblasts and myotubes [58]. Furthermore, the
FOLFIRI regimen, of which IRI is a constituent, has been previously shown to induce acute skeletal
muscle mitochondrial perturbations, highlighted by impaired mitochondrial biogenesis and enhanced
pro-oxidant signaling [11]. This suggests that the metronomic delivery of IRI potentially instigates
mitohormesis in skeletal muscle, where, initially, there is an acute metabolic challenge exerted upon
mitochondria from IRI administration; however, with repeat insults from IRI, mitochondria adapt
and become more adept at handling the prolonged metabolic challenge [91]. In this scenario, PARP-1
inhibition would transiently enhance the mitochondrial adaptations to the metabolic challenges by
protecting against nicotinamide adenine dinucleotide (NAD) depletion and, through the promotion
of DJ-1, aiding metabolic re-programming [92]. This hypothesis is based on the assumption that
these mitohormetic protective adaptations include increasing PARP activity, for example, PARylation,
which is activated during mitochondrial DNA repair and integrity maintenance [93] at the expense of
depleting NAD and impairing mitochondrial function.
3.5. Limitations
There were some limitations to our research that are worthy of mention. In the first instance,
we conducted our study using 6-week-old mice and treated them over 2 weeks, up to 8 weeks of
age. Mice are considered sexually mature at 8 weeks of age; hence, we treated our mice during the
pubertal developmental period but measured the impact of treatment at sexual maturity. Cachexia is
well documented in pediatric cancer patients and involves both tumor- and chemotherapy-mediated
pathogenesis [94]. Notably, however, pediatric cancer cachexia differs from adult cachexia in that
it predominantly manifests as stunted growth [95] which, along with significant skeletal muscle
dysfunction, can persist throughout the lifespan [96]. While the cachexia observed in our IRI-treated
mice may have included an element of growth repression, we also observed loss of body, lean and
fat mass from the pre- to post-treatment period, which is consistent with the accepted definition of
cachexia [1]. Secondly, our experimental design lacked a BGP-15-only cohort. This would not have
been so problematic had BGP-15 not induced further inhibition of protein synthesis or expression of
the cytoskeletal mechanotransduction proteins, dystrophin and β-dystroglycan on top of that already
elicited by IRI. That being said, we postulate that these effects of BGP-15 are specific to its activity in an
IRI-induced cellular stress environment since induction of HSP-72 and repression of PARP-1 have been
previously associated with enhanced protein synthesis and skeletal muscle accretion [97].
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4. Materials and Methods
4.1. Animals
4.1.1. Ethical Approval
All experimental procedures were approved by the Victoria University Animal Ethics Committee
(AEETH15/006) and conformed to the Australian Code of Practice for the Care and Use of Animals for
Scientific Purposes.
4.1.2. Experimental Design and Treatments
Male Balb/c mice were acquired from the Animal Resource Centre (ARC, Western Australia) and
randomly allocated to treatment groups (n = 8) upon arrival. Mice were housed on a 12-h light/dark
cycle with ad libitum access to food (i.e., standard mice chow) and water supply throughout the
experiments. Mice were administered either vehicle (VEH; 0.1% dimethyl sulfoxide (DMSO) in sterile
water), irinotecan (IRI; 30 mg/kg (Sigma Aldrich, Sydney, Australia) dissolved in 0.1% DMSO) or BGP-15
adjuvant therapy with IRI (IRI+BGP; 15 mg/kg (BGP-15 donated by N-gene Research Laboratories,
New York, NY, USA) dissolved in 0.1% DMSO). Treatments were administered via intraperitoneal
injection six times over a fifteen-day period (i.e., on days 1, 3 5, 8, 10 and 12). The cumulative dose of IRI
administered is equivalent to the 180 mg/m2 cumulative dose utilized in standard clinical regimens [98],
as previously described by us [99], while the dose of BGP-15 is equivalent to that previously used by our
group to protect against chemotherapy-induced skeletal myopathy [36]. Animals were weighed prior
to the commencement of treatment (PRE) on each day of treatment and at the experimental endpoint.
Food and water consumption were monitored throughout the duration of the treatment protocol.
4.2. Body Composition
Echo magnetic resonance imaging (echoMRI) was utilized to assess the effect of IRI treatment and
BGP-15 adjuvant therapy on body composition indices of lean and fat mass. Live mice were placed
into an echoMRI body composition analyzer (EMR-150, Echo Medical Systems, Houston, TX, USA) on
day 1 (Pre) and day 15 (Post) of the treatment protocol, as previously described [8]. Lean and fat mass
was quantified via triplicate scans spaced 30 s apart and reported as the mean of these triplicate scans.
4.3. Physical Activity Assessment
To evaluate the impact of IRI treatment and BGP-15 adjuvant therapy on the physical activity
of mice, animals were individually housed for 24 h immediately prior to treatment commencement
and the experimental endpoint in Promethion Metabolic cages (Sable Systems, Las Vegas, NV, USA).
Cages allowed free access to food, water and a running wheel. Real-time voluntary activity associated
with wheel running and general cage-based ambulatory activity was evaluated as described by us
previously [8,36]. Data presented pertain to the total 24-h post-treatment period.
4.4. Surgery
At the conclusion of the treatment regimen and following the final echoMRI scan, mice were deeply
anesthetized via isoflurane inhalation and administered an intraperitoneal injection of 0.040 µmol/g
puromycin (Millipore, Sydney, Australia) dissolved in 100 µL of 0.9% saline to measure protein
synthesis [45]. Thereafter, non-recovery surgery was performed. Muscles of interest were surgically
excised for ex vivo analysis in the following order: (1) left and right flexor digitorum brevis (FDB)
muscles for the measurement of mitochondrial functional parameters; (2) right extensor digitorum
longus (EDL) and soleus (SOL) muscles for the assessment of contractile properties. Following this, at
exactly 30 min after the injection of puromycin: (3) right tibialis anterior (TA) muscles were harvested
and immediately snap-frozen for Western blotting experiments; and (4) the left TA was weighed and
Cancers 2020, 12, 3810 18 of 28
prepared for histological assessment prior to snap-freezing. The remaining tissues were then harvested
(i.e., the left EDL and SOL and the heart), weighed and snap-frozen.
4.5. Ex Vivo Skeletal Muscle Contractile Function
Ex vivo evaluation of skeletal muscle contractile properties was performed as previously described
by us [100–102], using the predominantly fast-twitch fiber EDL and the predominately slow-twitch
fiber SOL muscles. These muscles were exposed and loops were tied at both tendons with 4.0 surgical
silk thread before being dissected from the hindlimb and placed into individual organ baths of a
Myodynamics Muscle Strip Myograph System (DMT-Asia Pacific, Bella Vista, Australia). Each organ
bath was filled with Krebs solution (NaCl 118 mM, MgSO4·7H2O 1 mM, KCl 4.75 mM, Na2HPO
1 mM, CaCl2 2.5 mM, NaHCO3 24 mM and glucose 11 mM; pH 7.4) infused with carbogen (5% CO2
in O2) and maintained at a temperature of 30 ◦C. The proximal end of the muscle was tied to the
force transducer, while the distal end was tied to a micromanipulator, with stimulating electrodes
flanking the muscle belly. Data were collected and analyzed using LabChart Pro version 8.0 software
(ADInstruments, Bella Vista, Australia). Initially, the optimal length (Lo) of each muscle was established
through the delivery of sequential twitch contractions, whilst incrementally stretching each muscle,
until the point where the greatest force that was produced by the muscle was found and the length
of the muscle at this point was measured with calipers. Once Lo was determined, a force–frequency
protocol was performed utilizing supramaximal square wave 0.2-ms pulses at an incremental range of
frequencies (i.e., 10, 20, 30, 40, 50, 60 80, 100, 120 and 150 Hz), with a 3-min rest period in between
each stimulation to prevent fatigue. The training duration of pulses was 350 and 500 ms for the EDL
and SOL muscles, respectively, due to their differing muscle fiber characteristics. The muscles were
then stimulated with three single-twitch contractions for the analysis of basic contractile properties,
i.e., peak twitch force (Pt), time to peak (TTP), half relaxation time ( 12 RT) and maximum rate of force
development (df/dt). To investigate fatigue susceptibility, muscles next underwent a three-minute
fatigue protocol, where EDL muscles were tetanically stimulated as above at 100 Hz, while SOL
muscles were tetanically stimulated every two seconds at 80 Hz to elicit a comparable level of fatigue.
Absolute force (Po) was considered as the force produced from the first tetanic response stimulated
during the fatigue protocol. Specific force (sPo) was assessed as a normalized force relative to the
physiological cross-sectional area (CSA) which takes into consideration three key variables of force
production (i.e., muscle mass, optimal length and muscle density (∼1.06 mg mm−3)), and was calculated
using the equation sPo = Po × (muscle mass/1.06 × Lo × fiber length:muscle length ratio), as previously
described [103].
4.6. Mitochondrial Respiratory Phenotyping
4.6.1. Flexor Digitorum Brevis Muscle Fiber Isolation
In order to conduct mitochondrial metabolic profiling, FDB muscles were harvested from both
feet and fibers were isolated using a protocol established by Schuh et al. [104], as performed by us
previously [36,102,105]. FDB muscles were incubated in 1 mL of pre-warmed dissociation medium
(Dulbecco’s modified Eagle medium (DMEM), Gibco 10566016; 2% FBS, Bovogen Biologicals; 4 mg/mL
collagenase A, Roche 10103586001; 50 µg/mL gentamycin, Sigma Aldrich, Sydney, Australia, G1397)
for 1 h and 45 min (37 ◦C, 5% CO2). Following this dissociation period, FDB bundles were placed into
~1.5 mL of incubation medium (DMEM, high glucose, GlutaMAX™ supplement, Gibco/Thermo Fisher
Scientific, Scoresby, Australia 10566016; 2% FBS, Bovogen Biologicals; 50 µg/mL gentamycin, Sigma
Aldrich G1397) and triturated with pipette tips of decreasing bore size to yield single fibers.
4.6.2. Seahorse Microplate Preparation
To facilitate fiber adherence to Seahorse XF24 cell culture V7 microplates (Seahorse Bioscience,
Mulgrave., Australia), wells were coated with 5 µL of extracellular matrix (Sigma Aldrich, Sydney,
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AustraliaE1270) diluted in DMEM (1:1). Then, 75 µL of isolated FDB fibers was aliquoted into coated
wells and confluency was determined using light microscopy. A minimum of ~60% confluency, i.e.,
the estimated percentage of the well bottom covered by isolated FDB fibers, was deemed optimal. If a
well did not meet this requirement, an additional 50 µL aliquot of fibers was dispensed into wells.
4.6.3. Mitochondrial Metabolic Profiling Using the XF24 Extracellular Flux Analyzer
Mitochondrial metabolic profiling was performed using extracellular flux analysis (Seahorse
Bioscience/Agilent, Mulgrave, Australia) as described by us previously [105]. Basal, phosphorylating,
maximal and non-mitochondrial respiration was measured initially through the sequential addition
of 2 µg/mL oligomycin, 400 nm carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) with
10 mM sodium pyruvate, and 1 µM antimycin A, respectively. The extracellular acidification rate
(ECAR) was concomitantly measured as an indicator of anaerobic glycolysis.
4.7. Skeletal Muscle Histology
All histological experiments were completed as previously described by us [36,105]. To determine
whether IRI had atrophic effects on skeletal muscle and, subsequently, whether BGP-15 adjuvant
therapy could rescue any atrophy, we histologically assessed TA muscles which were cryopreserved in
optimal cutting temperature compound (Sakura Finetek, Maumee, OH, USA). TAs were sectioned
(10 µm, −20◦C, Leica CM1950, Leica Biosystems, Mount Waverley, Australia) and mounted onto glass
slides and then stained with hematoxylin and eosin (H&E) to evaluate muscle fiber size through
CSA. All slides were imaged on a Zeiss Axio Imager Z2 microscope (Carl Zeiss MicroImaging GmbH,
Oberkochen, Germany) at 20× magnification and analyzed as described previously [36,105] using
ImageJ software (NIH, Bethesda, MD, USA).
4.8. Western Blot Analyses
Western blotting was utilized to explore the effect of IRI treatment and BGP-15 adjuvant therapy on
molecular signaling pathways surrounding protein synthesis and degradation, cell stress and membrane
structure. All Western blotting protocols were completed as previously described by us [45,105]. Frozen
TA muscles were homogenized using an Omni Tissue Homogenizer (TH220, Omni International,
Kennesaw, GA, USA) for 20 s in ice-cold Western immunoprecipitation kinase (WIK) buffer (40 mM
Tris, pH 7.5; 1 mM ethylenediaminetetraacetic acid (EDTA); 5 mM etheylen glycol-bis(β-aminoethyl
ether)-N, N, N’, N’-tetraacetic acid (EGTA); 0.5% TritonX-100; 25 mM β-glycerophosphate; 25 mM
NaF; 1 mM Na3VO4; 10 g/mL leupeptin; and 1 mM phenylmethylsulfonyl fluoride (PMSF). Muscle
homogenate was centrifuged at 3500 rpm for 5 min at 4 ◦C, before the pellet was resuspended and the
muscle homogenate was frozen for further analysis. Protein concentrations were determined using
a sample assay kit (Bio-Rad Laboratories, Hercules, CA, USA) to ensure equal loading on the gels.
Samples were prepared with equivalent amounts of protein in either 2× sodium dodecyl sulfate (SDS)
sample buffer (20% (v/v) glycerol; 100 mM Tris-Base, pH 6.8; 4% (w/v) SDS; 0.017% (w/v) bromophenol
blue; 0.25 M dithiothreitol (DTT)) or 4× Laemmli buffer (Bio-Rad Laboratories, Hercules, CA, USA)
reduced in 50 mM DTT, heated for 5 min at 95 ◦C and subjected to electrophoretic separation on 7.5–12%
SDS-acrylamide gels. Antibodies that required exceptions to this protocol include Total oxidative
phosphorylation (OXPHOS) cocktail (1:1000; ab110413; Abcam, Cambridge, UK), where samples were
heated for 5 min at 40 ◦C, and anti-α-sarcoglycan (1:200; IVD3(1)A9; Developmental Studies Hybridoma
Bank (DSHB)), which was probed in samples under non-denaturing and non-reducing conditions,
as per supplier recommendations. Following electrophoretic separation, proteins were transferred
to a polyvinylidene fluoride membrane, blocked with 5% not-fat milk powder in Tris-buffered saline
containing 0.1% Tween 20 (TBST) for 1 h followed by an overnight incubation at 4 ◦C with primary
antibody dissolved in TBST containing either 1% BSA or 3% non-fat milk powder. The following
primary antibodies were used: anti-phospho 4E-BP1(Thr37/46) (1:1000; #2855; Cell Signalling Technology
(CST, Danvers, MA, USA)), anti-4E-BP1 (1:1000; #9452; CST), anti-4-HNE (1:1000; ab46545; Abcam,
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Cambridge, UK), anti-phospho AktSer473 (1:2000; #4060; CST), anti-phospho AktThr308 (1:2000; #13038;
CST), anti-Akt (1:1000; #4691; CST), anti-Atrogin-1 (1:1000; AP2041; ECM Biosciences, Versailles, KY,
USA), anti-β-Dystroglycan (1:500; MANDAG2 (7D11); DSHB), anti-Cytochrome C (1:2000; #11940,
CST), anti-δ-Sarcoglycan (1:1000; ab137101; Abcam), anti-Desmin (1:1000; #5332; CST), anti-DJ-1 (1:1000;
#5933; 1:1000), anti-Dystrophin (1:200; ab15277; Abcam), anti-phospho eIF2aSer51 (1:1000; #3398; CST),
anti-eIF2a (1:1000; #5324; CST), anti-phospho ERK1/2(Thr202/Tyr204) (1:1000; #9101; CST), anti-ERK1/2
(1:1000; #9102; CST), anti-HO-1 (1:1000; ADI-SPA-896; Enzo Life Sciences, Farmigdale, NY, USA),
anti-HSP-70 (1:1000; ADI-SPA-812; Enzo Life Sciences), anti-phospho JNK(Thr183/Tyr185) (1:1000; #4668;
CST), anti-JNK (1:1000; #9252; CST), anti-Keap-1 (1:1000; #8047; CST), anti-Laminin (1:2000; L9393;
Sigma-Aldrich, Sydney, Australia), anti-MMP-2 (1:1000; ab92536; Abcam), anti-MMP-9 (1:300; AF909;
R&D Systems), anti-MuRF-1 (1:200; AF5366; R&D Systems, Minneapolis, MN, USA); anti-NRF-2
(1:1000; #12721, CST), anti-phospho p38(Thr180/Tyr182) (1:1000; #4511; CST), anti-p38 (1:1000; #9212; CST),
anti-phospho p70s6k(Thr389) (1:1000; #9234; CST), anti-p70s6k (1:1000; #2708; CST), anti-PARP-1 (1:1000;
9542, CST), anti-Puromycin (1:5000; MABE343; Merck Millipore, Bayswater, Australia), anti-Rac1 (1:500;
#05-389; Merck Millipore), anti-SOD1 (1:3000; ADI-SOD-101; Enzo Life Sciences) and anti-Ubiquitin
(1:3000; sc8017; Santa Cruz, Dalla, TX, USA). After overnight incubation, membranes were washed 3
separate times for 10 min each in TBST and then probed with a horseradish peroxidase-conjugated
secondary antibody (1:5,000; anti-rabbit IgG, 1:5,000; anti-goat IgG or 1:20,000; anti-mouse IgG,
Vector Laboratories, Burlingame, CA, USA) in 5% not-fat milk powder in TBST for 1 h at room
temperature. Membranes that were probed with anti-Puromycin were incubated in anti-mouse IgG Fc
2a-specific horseradish peroxidase-conjugated secondary antibody (1:50,000; Jackson ImmunoResearch
Laboratories Inc., West Grove, PA, USA), as previously described [45]. Following another set of
3 separate 10-min washes in TBST, the blots were developed with a DARQ CCD camera mounted
to a Fusion FX imaging system (Vilber Lourmat, Eberhardzell, Germany) using ECL Prime reagent
(Amersham, Piscataway, NJ, USA). Once images were captured, the membranes were stained with
Coomassie Blue and then normalized to total protein. Densitometric measurements were carried out
using FusionCAPTAdvance software (Vilber Lourmat, Eberhardzell, Germany).
4.9. Citrate Synthase Activity
Citrate Synthase (CS) activity was measured as a marker of mitochondrial density and/or
anaplerosis. Homogenized TA muscles in WIK buffer (as described above) were added to the reagent
cocktail (100 mM Tris Buffer, 1 mM 5,5′-Dithiobis(2-nitrobenzoic acid) (DTNB) and 3 mM Acetyl
CoA), and to initiate the reaction, oxaloacetate (10 mM) was added just prior to measuring CS activity
spectrophotometrically (412 nm, 25 ◦C, 5 min). CS activity was calculated using the extinction coefficient
of 13.6 [106] and expressed relative to muscle wet weight.
4.10. Zymography Analyses for Gelatinase Activity
Zymography was performed via gelatin-infused SDS-PAGE to detect the gelatinolytic activity of
matrix metalloproteinases (MMPs), specifically the isoforms MMP-2 and MMP-9, based on a previously
established protocol [56]. EDL muscles were placed in ice-cold zymography homogenization buffer
(50 mM Tris-HCl; 150 mM NaCl; 10 mM CaCl2; pH 7.5) and were homogenized using the Omni Tissue
Homogenizer (TH220, Omni International, Kennesaw, GA, USA) for 3 sets at medium speed for 8 s.
Muscle homogenate was centrifuged at 3500 rpm for 5 min at 4 ◦C, before the pellet was resuspended
and the muscle homogenate frozen for further analysis. Protein concentrations were determined using
an RC DC sample assay kit (Bio-Rad Laboratories, Hercules, CA, USA) to ensure equal loading on the
gels. Samples were then prepared in 4X SDS sample buffer (400 mM Tris-HCl, pH 6.8; 4% (w/v) SDS;
20% glycerol (v/v); 0.005% (w/v) bromophenol blue) under non-reducing, non-denaturing conditions,
with 100 µg of protein loaded onto 0.75-mm thick 7.5% SDS-acrylamide gels that were co-polymerized
with 1% (w/v) gelatin (Sigma, Sydney, Australia). After gel electrophoresis was completed, gels were
washed twice for 40 min in denaturing buffer (2.5% (v/v) Triton-X; 50 mM Tris-HCl; 5 mM CaCl2; pH 7.6)
Cancers 2020, 12, 3810 21 of 28
to remove SDS. After this, gels were washed twice for 15 min in renaturing buffer (50 mM Tris-HCl;
5 mM CaCl2; pH 7.6) before being incubated overnight (~18 h) at 37 ◦C in developing buffer (50 mM
Tris-HCl; 150 mM NaCl; 10 mM CaCl2; 1 µM ZnCL2; 0.02% (w/v) NaN3; pH 7.5). The gels were then
stained for 3 h in Coomassie Blue solution (0.05% (w/v) Coomassie Brilliant Blue; 30% (v/v) methanol;
10% (v/v) acetic acid) before being incubated for 3 h in de-stain solution (30% (v/v) methanol; 10%
(v/v) acetic acid), allowing the visualization of the digestion of gelatin (i.e., gelatinase activity) against
the dark blue background. Gels were imaged using an Epson Perfection V700 Photo Scanner (Epson,
Sydney, Australia). Samples were run in duplicate on separate gels, with images semi-quantitatively
analyzed using Image J software (NIH, Bethesda, MD, USA), according to a previously established
method [107], with the mean area density reported.
4.11. Statistics
Data are presented as mean ± standard error of the mean (SEM). Data were analyzed using
GraphPad prism v8 (GraphPad Software, San Diego, CA, USA). A one-way ANOVA with Tukey’s
post-hoc test was utilized to detect treatment differences for parametric data, while Dunn’s multiple
comparison test was utilized to analyze non-parametric data, with an α-value of 0.05 considered
significant. A two-way repeated measures ANOVA was used to detect differences between treatment
and stimulation frequency/time for force–frequency relationships and fatigue susceptibility studies,
with Tukey’s post-hoc test utilized for multiple comparisons.
5. Conclusions
This study shows, for the first time, that, independent of cancer, IRI treatment diminishes body
mass indices, underlined by reduced skeletal muscle mass and, subsequently, contractile function,
which were mitigated by the PARP inhibitor BGP-15. The protective effect of BGP-15 adjuvant therapy
occurred alongside a paradoxical reduction in protein synthesis rates, likely underlined by aberrant
proteostasis; however, this needs to be confirmed. Additionally, IRI treatment and BGP-15 reduced
mTORC2 signaling and caused changes to the expression of cytoskeletal mechanotransduction proteins
associated with the DAPC in a step-like manner that mirrored the reduction in protein synthesis rates.
These data highlight remodeling of the contractile apparatus, cytoskeleton and/or ECM that is induced
by IRI and even more so by IRI+BGP-15. It is difficult to conclude from our data whether BGP-15, when
teamed with IRI treatment, is beneficial for the skeletal muscular system or not, since on the one hand,
BGP-15 mitigated many of the cachectic side-effects of IRI treatment, but on the other hand, it made
fast-twitch muscles more prone to tearing, despite rescuing function. Time-course studies should
be undertaken to determine whether the down regulation of DAPC constituent proteins evoked by
both IRI and IRI+BGP-15 induces a muscular dystrophy-like phenotype in the long term. This aspect
should be of significant clinical consideration before instigating the mainstream use of PARP inhibitors
in anti-cancer treatment and when prescribing IRI-based chemotherapy regimens to patients, since the
maintenance of body and, particularly, skeletal muscle mass improves patient survival and long-term
outcomes during cancer treatment.
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